Seventeen paediatric patients from 0.3 to 19 years old were studied to determine the individual dose-response curves and the maintenance requirements of alcuronium during N 2 0-O[opioid anaesthesia. Alcuronium 300 J1g/kg maintained the mean (SD) neuromuscular block at 90-95%for 62 (34 min). This time was longest in patients of < 1 year of age (92 min). The hourly maintenance requirement ofalcuronium was 0.41 (0.12) times the individual ED95 dose. This value was comparable in infants, children and adolescents and indicates similar duration of effect of alcuronium in all paediatric age groups.
There have been few studies on alcuronium, a nondepolarizing neuromuscular blocking agent, although the drug has been widely used in clinical anaesthesia. [1] [2] [3] [4] Adult pharmacokinetic studies show an elimination half-life of 200 minutes and a distribution volume comparable to other muscle relaxants. 5 These data suggest that the duration of effect following alcuronium should be longer than following pancuronium, although the clinical impression has often been the opposite. The only paediatric study on alcuronium showed the ED95 dose of 2 70 ~g/kg in children from one to ten years of age. 6 The aim of the present study was to determine the maintenance requirement of alcuronium in paediatric patients and to evaluate the duration of effect by correlating individual ED9,'i doses to individual maintenance reqUIrements during N 2 0-0 2 -opioid anaesthesia.
PATIENTS AND METHODS
Seventeen paediatric patients (ASA physical status 1-11) were studied following Institutional Ethical Committee approval. The patients were to undergo a general surgical procedure with an expected duration of more than two hours. None of the patients had any disease or medication known to effect neuromuscular transmission. Four Accepted for publication June 20, 1990 patients were < 1 year old (infants), seven were 1-10 years old (children) and six patients were > 10 years old (adolescents).
Chloral hydrate 40 mg/kg or diazepam 0.3 mg/kg were used as oral premedication. Anaesthesia was induced with sodium thiopentone 3-5 mg/kg and nitrous oxide in oxygen 2: 1. N 2 0 in O~ was continued during maintenance of anaesthesIa and either fentanyl 2-4 ~g/kg/h or morphine 0.2-0.3 mg/kg was used for analgesia. No volatile anaesthetic agents were used. End-tidal carbon dioxide was maintained at 38 to 42 mmHg and palmar skin temperature greater than 34°C. Blood loss never exceeded 5% of estimated blood volume. Hartmann's solution was administered at a rate of 4-6 mlIkg/h. Surface electrodes to stimulate the ulnar nerve and to record the adductor pollicis electromyographic response were applied when the patient had fallen asleep. The neuromuscular transmission monitor (Relaxograph®, Datex, Helsinki, Finland) then was calibrated. Train-offour series of supramaximal2 Hz stimuli were used at 20 second intervals. Alcuronium was administered in increments of 50 to I 00 ~g/kg to create the individual cumulative dose-response curve after the calibration signal remained stable. Patients were intubated when the neuromuscular block (depression of the first twitch response in the train-of-four series) was > 90%. Subsequently, alcuronium was given in increments of 1/5 of the individual ED95 dose whenever the twitch response recovered to 15% of the calibration value. The Anaesthesia and Intensive Care, Vol. 18, No. 4, November, 1990 Alcuronium requirement Age, years FIGURE I.-Individual alcuronium requirements to maintain a 90-95% neuromuscular block during N 20-0~ opioid anaesthesia. When the hourly requirement IS related to individual ED9~ of alcuronium, it is not influenced by the age ot the paediatric patient.
residual neuromuscular block was reversed with neostigmine 50 ~g!kg at the end of anaesthesia.
The dose-response data were transformed to logarithm and probit values to calculate the individual ED9~ dose of alcuronium. 7 The alcuronium requlfement to maintain a 90-95% neuromuscular block following endotracheal intubation was calculated in ~g!kg!h. This was averaged for the two hours of anaesthesia following the first increment. The maintenance requirement was also related to the individual ED.9S dose of alcuronium to reflect the duration ot effect of alcuronium in paediatric patients. Analysis of variance and linear regression analysis were used when appropriate. A P-value of < 0.05 was regarded as significant. Mean values (SD) are shown.
RESULTS
The ED9S dose of a1curonium was 190 (30) ~g!kg in infants and 260 (60) ~g!kg in patients> 1 year old (P< 0.01). The mean maximal neuromuscular block at the time of endotracheal intubation was 95 (2)%, that is 5 (2)% of the original twitch response. Thereafter the twitch response recovered to 15% in 22 (9) minutes.
Individual neuromuscular block averaged 92 (2)% during the maintenance of anaesthesia. Hourly a1curonium requirement was least in infants at 80 (1 9) ~g!kg!h and greatest in children of 1-10 years in whom it was 110 (25) ~g!kg!h. The hourly requirement was comparable in infants, children and adolescents when it was related to the individual ED9S dose 0.43 (0.13), 0.42 (0.12) and 0.40 (0.15) times ED9S dose, respectively.) (Figure 1 ). DISCUSSION This study shows that the average a1curonium requirement to maintain a 90-95% neuromuscular Elimination half-life, min We used the fraction of individual ED9S dose required hourly as an indication of the duration of effect of the muscle relaxant. If this method is reliable, it offers enormous potential for further studies on muscle relaxants as no blood samples are necessary to reach this fractional figure. Shanks recently reviewed nondepolarizing muscle relaxants and gave median adult pharmacokinetic and pharmocodynamic data for atracurium, vecuronium, pancuronium, gallamine, alcuronium, tubocurarine and metocurine. s A significant correlation exists between the fraction of ED 2S dose required hourly and the elimination half-lite of the relaxant when the data are taken from his tables (r = 0.988, P < 0.001) ( Figure 2 ).
Our previous studies on atracurium, vecuronium and pancuronium in paediatric patients fit well with the data of Figure 2 ; hourly maintenance requirement of atracurium and vecuronium were 1.8-2.0 times the ED9S dose and of pancuronium 0.6 times the ED9S dose. 8 -IO The elimination halflives of these relaxants in children are 19, 41 and 103 minutes, respectively. I 1-13 There are no available pharmacokinetic data for alcuronium in paediatric patients. Our results suggest an elimination half-life longer than that of pancuronium, a result comparable to adult data. 5 This finding is supported by the data on spontaneous recovery rates following an ED95 dose. Twitch height recovers from 5 to 25% in eIghteen minutes after pancuronium, but only to 12% following alcuronium.
Nonetheless, the clinical impression remains that alcuronium is a shorter acting agent than pancuronium, although our data suggest the opposite. The logical explanation may reside in the doses commonly used during clinical anaesthesia, alcuronium (250 Jlg/kg) and pancuronium (100 Jlglkg). The first dose is less than the ED95 of alcuronium in children and adolescents but the dose for pancuronium is 1.2 times the ED9~ of pancuronium in those age groupS.6,IO It is ObVIOUS that the neuromuscular block will recover more quickly following a small dose of alcuronium than following a large dose of pancuronium. Therefore, the clinical impression of a brief duration of action arises only because relatively small doses of alcuronium are used in clinical practice.
In conclusion, our data show that the average requirement of alcuronium to maintain a 90-95% neuromuscular block during N 2 0-0 2 -opioid anaesthesia in paediatric patients is 96 (25) Jlg/kg/h. This requirement is 0.4 (0.1) times the individual ED95 dose of alcuronium and indicates that alcuronium is a long acting muscle relaxant in all paediatric patients. The duration of effect may be slightly longer than following an equipotent dose of pancuronium.
